Difference between revisions of "Atypical hemolytic uremic syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="text-align:center; width:100%;" !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' |- |style="background-color:#F0F0F0; width:15%"|[[File:Shrut...) |
m |
||
(35 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|heme}} | |
− | | | + | *''We have moved [[How I Treat]] articles to a dedicated page.'' |
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=All lines of therapy= | =All lines of therapy= | ||
− | |||
==Eculizumab monotherapy {{#subobject:24195b|Regimen=1}}== | ==Eculizumab monotherapy {{#subobject:24195b|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:8ceb84|Variant=1}}=== | ||
+ | {| class="wikitable" style="color:white; background-color:#404040" | ||
+ | |<small>'''FDA-recommended dose'''</small> | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
− | + | !style="width: 33%"|Study | |
− | {| class="wikitable" style="width: | + | !style="width: 33%"|Dates of enrollment |
− | !style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: | + | |- |
+ | |[https://doi.org/10.1056/NEJMoa1208981 Legendre et al. 2013 (C08-002)] | ||
+ | |NR | ||
+ | |style="background-color:#91cf61"|Phase 2 (RT) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1056/NEJMoa1208981 Legendre et al. 2013 (C08-003)] |
− | |style="background-color:#91cf61"|Phase | + | |NR |
+ | |style="background-color:#91cf61"|Phase 2 (RT) | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ Cofiell et al. 2015 (C10-004)] |
− | |style="background-color:#91cf61"| | + | |NR |
+ | |style="background-color:#91cf61"|Non-randomized (RT) | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/j.kint.2015.11.026 Greenbaum et al. 2016 (C10-003)] |
− | |style="background-color:#91cf61"| | + | |NR |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | ''Eligible patients enrolled in | + | ''Note: Eligible patients enrolled in C10-004 had platelet counts less than 150 x 10<sup>9</sup>/L, hemoglobin levels less than or equal to the lower limit of normal, LDH levels greater than or equal to 1.5x upper limit of normal, serum creatinine levels greater than or equal to the upper limit of normal, ADAMTS13 activity greater than or equal to 5%, and no positive Shiga toxin-producing ''Escherichia coli'' test.'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Eculizumab (Soliris)]] as follows: | *[[Eculizumab (Soliris)]] as follows: | ||
− | ** | + | **Cycles 1 to 4: 900 mg IV once on day 1 |
− | **Cycle | + | **Cycle 5 onwards: 1200 mg IV once on day 1 |
− | + | ====Supportive therapy==== | |
− | ====Supportive | ||
* Patients were vaccinated against ''Neisseria meningitidis'' or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose | * Patients were vaccinated against ''Neisseria meningitidis'' or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose | ||
+ | '''7-day cycle for 4 cycles, then 14-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # '''C08-002:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/study/NCT00844545 NCT00844545]; [https://clinicaltrials.gov/study/NCT00844844 NCT00844844] | ||
+ | # '''C08-003:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/study/NCT00838513 NCT00838513]; [https://clinicaltrials.gov/study/NCT00844428 NCT00844428] | ||
+ | # '''C10-004:''' Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. [https://doi.org/10.1182/blood-2014-09-600411 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25833956/ PubMed] [https://clinicaltrials.gov/study/NCT01194973 NCT01194973] | ||
+ | # '''C10-003:''' Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar;89(3):701-11. Epub 2016 Jan 28. [https://doi.org/10.1016/j.kint.2015.11.026 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26880462/ PubMed] [https://clinicaltrials.gov/study/NCT01193348 NCT01193348] | ||
− | + | ==Ravulizumab monotherapy {{#subobject:abd213 |Regimen=1}}== | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
+ | ===Regimen {{#subobject:8cehr3|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/j.kint.2020.01.035 Rondeau et al. 2020 (ALXN1210-aHUS-311)] | ||
+ | |NR | ||
+ | |style="background-color:#91cf61"|Nonrandomized Phase 3 | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7910247/ Tanaka et al. 2020 (ALXN1210-aHUS-312)] | ||
+ | |NR | ||
+ | |style="background-color:#91cf61"|Nonrandomized Phase 3 | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Immunosuppressive therapy==== | ||
+ | *[[Ravulizumab (Ultomiris)]] | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''ALXN1210-aHUS-311:''' Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020 Jun;97(6):1287-1296. Epub 2020 Mar 6. Erratum in: Kidney Int. 2020 Dec;98(6):1621. Erratum in: Kidney Int. 2021 May;99(5):1244. [https://doi.org/10.1016/j.kint.2020.01.035 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32299680/ PubMed] [https://clinicaltrials.gov/study/NCT02949128 NCT02949128] |
− | # | + | #'''ALXN1210-aHUS-312:''' Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021 Apr;36(4):889-898. Epub 2020 Oct 13. Erratum in: Pediatr Nephrol. 2020 Dec 9. [https://doi.org/10.1007/s00467-020-04774-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7910247/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33048203/ PubMed] [https://clinicaltrials.gov/study/NCT03131219 NCT03131219] |
[[Category:Atypical hemolytic uremic syndrome regimens]] | [[Category:Atypical hemolytic uremic syndrome regimens]] |
Latest revision as of 13:11, 29 June 2024
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
- We have moved How I Treat articles to a dedicated page.
2 regimens on this page
2 variants on this page
|
All lines of therapy
Eculizumab monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Legendre et al. 2013 (C08-002) | NR | Phase 2 (RT) |
Legendre et al. 2013 (C08-003) | NR | Phase 2 (RT) |
Cofiell et al. 2015 (C10-004) | NR | Non-randomized (RT) |
Greenbaum et al. 2016 (C10-003) | NR | Phase 2 |
Note: Eligible patients enrolled in C10-004 had platelet counts less than 150 x 109/L, hemoglobin levels less than or equal to the lower limit of normal, LDH levels greater than or equal to 1.5x upper limit of normal, serum creatinine levels greater than or equal to the upper limit of normal, ADAMTS13 activity greater than or equal to 5%, and no positive Shiga toxin-producing Escherichia coli test.
Immunosuppressive therapy
- Eculizumab (Soliris) as follows:
- Cycles 1 to 4: 900 mg IV once on day 1
- Cycle 5 onwards: 1200 mg IV once on day 1
Supportive therapy
- Patients were vaccinated against Neisseria meningitidis or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose
7-day cycle for 4 cycles, then 14-day cycles
References
- C08-002: Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. link to original article PubMed NCT00844545; NCT00844844
- C08-003: Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. link to original article PubMed NCT00838513; NCT00844428
- C10-004: Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. link to original article link to PMC article contains dosing details in manuscript PubMed NCT01194973
- C10-003: Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar;89(3):701-11. Epub 2016 Jan 28. link to original article PubMed NCT01193348
Ravulizumab monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Rondeau et al. 2020 (ALXN1210-aHUS-311) | NR | Nonrandomized Phase 3 |
Tanaka et al. 2020 (ALXN1210-aHUS-312) | NR | Nonrandomized Phase 3 |
Immunosuppressive therapy
References
- ALXN1210-aHUS-311: Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020 Jun;97(6):1287-1296. Epub 2020 Mar 6. Erratum in: Kidney Int. 2020 Dec;98(6):1621. Erratum in: Kidney Int. 2021 May;99(5):1244. link to original article PubMed NCT02949128
- ALXN1210-aHUS-312: Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021 Apr;36(4):889-898. Epub 2020 Oct 13. Erratum in: Pediatr Nephrol. 2020 Dec 9. link to original article link to PMC article PubMed NCT03131219